million people affected worldwide
Psychedelic research currently is in Preclinical
Schizophrenia and psychedelics have a long and intertwined history. First psychiatrists took LSD to better understand their patients as they believed that the acute LSD experience mirrored that of their patients. This perspective, of psychedelics as so-called psycho-mimetics persisted for a long time in academia and in the common understanding. Little research has been done on how psychedelics can help those with schizophrenia.
This topic is currently a stub, it will be expanded upon in the near future.
These are the institutes, from companies to universities, who are working on Schizophrenia.
These are some of the best-known people, from researchers to entrepreneurs, working on Schizophrenia.
David Walling is a clinical psychologist and serves as Chief Executive Officer and Principal Investigator for CNS.
Linked Research Papers about Schizophrenia
Rapid antidepressant effect of S-ketamine in schizophrenia
Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia
Drug models of schizophrenia
Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia
Lysergide Treatment of Schizophrenic and Nonschizophrenic Alcoholics; A Controlled Evaluation
MDMA for the Treatment of Negative Symptoms in Schizophrenia
Pharmacology of Hallucinations: Several Mechanisms for One Single Symptom?
Opposite alterations of 5HT2A receptor brain density in subjects with schizophrenia: relevance of radiotracers pharmacological profile
Psychedelics and schizophrenia: Distinct alterations to Bayesian inference